Risk factors
Bicara Therapeutics (BCAX) risk factors
Item 1A of every Bicara Therapeutics Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
76 risks, 9 new, 4 dropped, 18 reworded since the prior year. Clinical stage biopharmaceutical company Bicara Therapeutics focuses on developing its lead product candidate ficerafusp alfa, raising capital through public and private offerings, and managing regulatory and manufacturing dependencies.
Filed Mar 30, 2026 - FY2024 10-K risk factors
71 risks. Bicara Therapeutics relies heavily on the clinical and commercial success of its lead product candidate, ficerafusp alfa.
Filed Mar 27, 2025